Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish a registry of all children with severe, malignant
osteopetrosis who are treated with Actimmune (IFN-g 1b or Interferon gamma-1b) to monitor the
effects of IFN-g 1b on preventing progression of this disease and to follow the safety of
patients receiving it on a long-term basis. In addition, evaluation of the possible effect of
Actimmune therapy on the humoral response to normal childhood vaccinations in this same
patient population will be examined.Interferon gamma is a substance that the body makes
naturally.